Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AB Avenue BiosciencesCompany profile Develops high-throughput protein engineering technology for biologics manufacturing Develops high-throughput protein engineering technology for biologics manufacturing | $5.7M | Seed+Seed | Biotech | United States | Investors | |
| F FluoSpheraCompany profile Develops human-based preclinical platform for drug safety and efficacy testing Develops human-based preclinical platform for drug safety and efficacy testing | €1.2M | Undisclosed | Biotech | Switzerland | Investors | |
| VT Develops intelligent, logic-gated therapeutics for solid tumors | $61M | Series A | Biotech | China | Investors | |
| N Develops implant for treating articular cartilage defects in the knee | $4.1M | Seed2Seed | Biotech | United States | Investors | |
| V Provides intelligent software platforms for oncology care | $43M | Undisclosed | Biotech, Healthtech | United States | Investors | |
| MT Mirador TherapeuticsCompany profile Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases | $250M | Series B | Biotech | United States | Investors | |
| AA Allos AICompany profile Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. | $5M | Seed | Biotech, AI | United States | Investors | |
| TB Trailhead BiosystemsCompany profile Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine | $20M | Growth | Biotech | United States | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $70M | Series C1Series C+ | Biotech | China | Investors | |
| JT Develops regenerative biologics to restore tissue function | $33.5M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.